obesity and glp 1 GLP-1 Agonists For In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH GLP-1 Agonists In Obesity
Description
Outcomes included changes in left ventricular ejection fraction (LVEF), end-diastolic volume (LVEDV), end-systolic volume (LVESV), global longitudinal strain (GLS), left ventricular mass, left atrial volume (LAV), and NT-proBNP levels
This acquisition is aimed at enhancing its portfolio with the addition of Metsera's Next-Generation Obesity Portfolio.
GLP-1
Immediately accessible with a FREE canva account
Request an appointment at Medshape Texas, or call (832) 230-0375.
